Skip to main content

What the FDA labels say about taking them together

Quinidine and ubrogepant

Ubrogepant's FDA label of June 5, 2025 names quinidine in its drug interactions section; the quinidine label PlainMeds reads does not name ubrogepant. The ubrogepant label: “Use of BCRP and/or P-gp only inhibitors may increase the exposure of ubrogepant [ s ee Clinical Pharmacology ].”

Check it at the source: the quinidine FDA label on DailyMed (effective February 1, 2018, Sun Pharmaceutical Industries, Inc.); the ubrogepant FDA label on DailyMed (effective June 5, 2025, Allergan, Inc.).

What does the quinidine label say about ubrogepant?

Quinidine's label (effective February 1, 2018) does not name ubrogepant in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Quinidine Gluconate), Sun Pharmaceutical Industries, Inc., effective February 1, 2018 (SPL set 5023f053-fcc4-4c2c-aa59-9ec198ad185e), via openFDA; the full label on DailyMed

What does the ubrogepant label say about quinidine?

Ubrogepant label, drug interactions

Use of BCRP and/or P-gp only inhibitors (e.g., quinidine, carvedilol, eltrombopag, curcumin) may increase the exposure of ubrogepant [ s ee Clinical Pharmacology ( 12.3 ) ].

Source: FDA drug label (UBRELVY), NDA211765 (Abbvie), as published by Allergan, Inc., effective June 5, 2025 (SPL set fd9f9458-fd96-4688-be3f-f77b3d1af6ab), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

4Quinidine generic labelers
0Ubrogepant generic labelers
QuinidineUbrogepant
Labeled forAtrial fibrillationMigraine
Boxed warningYesNo
Pharmacy cost (NADAC)$4.92 per tablet 324 mg tablet$109.11 per tablet 100 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?